Denali Therapeutics (DNLI) AGM 2026 summary

Opening remarks and agenda

• Meeting called to order by the CEO, with introductions of directors and management in attendance.

• Virtual format continues to provide broader access for stakeholders globally.

• Attendance is by invitation only, with confirmation of proper notice and availability of proxy materials.

• Quorum confirmed, allowing the meeting to proceed with official business.

Board and executive committee updates

• Three Class III directors nominated for election, each to serve until the 2029 annual meeting.

• Board unanimously recommends voting for the nominated directors.

Shareholder proposals

• Election of three directors as Class III directors.

• Ratification of Ernst & Young as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Advisory approval of executive compensation.